In Merck’s case, worries over rising competition from so-called ‘biosimilar’ generic products, which approximate the biological chemical structure of branded medicines, is behind much of the ...

Person drowned at Half Moon Lake over weekend. By WEAU Staff. Published: Jun. 11, 2025 at 10:42 AM CDT EAU CLAIRE, Wis. (WEAU) - According to the Eau Claire Police Department and ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot received authorization from the U.S. Food and Drug Administration (FDA).

Stay up to date on how MoonLake Immunotherapeutics Class A (MLTX:XNAS) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.

In contrast, Goldman Sachs reaffirmed its Buy rating, highlighting Merck’s expansive oncology strategy and potential commercial opportunities exceeding $25 billion by the mid-2030s. Additionally, ...

Merck & Co., Inc. (NYSE:MRK) on Monday shared topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational ...

MoonLake shares climbed 5.5% from $39.01 to $41.16 on June 2, the day news of Merck’s interest in MoonLake surfaced, then jumped another 24% over two days to $51.05 Wednesday before fading 4% to ...

Merck made $3B+ offer for MoonLake earlier this year - report. MoonLake Immunotherapeutics is up ~25% in post-market trading Monday following a Financial Times report that Merck ...